Sernova Corp. (SVA.TO)
CAD 0.23
(0.0%)
CAD 0.23
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 41.13 Million CAD | 66.16% |
| 2022 | 24.75 Million CAD | 256.86% |
| 2021 | 6.93 Million CAD | 31.88% |
| 2020 | 5.25 Million CAD | 31.23% |
| 2019 | 4 Million CAD | 8.14% |
| 2018 | 3.7 Million CAD | 40.21% |
| 2017 | 2.64 Million CAD | 5.67% |
| 2016 | 2.5 Million CAD | -13.31% |
| 2015 | 2.88 Million CAD | 3.3% |
| 2014 | 2.79 Million CAD | 35.27% |
| 2013 | 2.06 Million CAD | -22.34% |
| 2012 | 2.65 Million CAD | 30.76% |
| 2011 | 2.03 Million CAD | 10.25% |
| 2010 | 1.84 Million CAD | 24.09% |
| 2009 | 1.48 Million CAD | -47.54% |
| 2008 | 2.83 Million CAD | -23.77% |
| 2007 | 3.71 Million CAD | 178.25% |
| 2006 | 1.33 Million CAD | 210.01% |
| 2005 | 430.94 Thousand CAD | -34.46% |
| 2004 | 657.48 Thousand CAD | -21.97% |
| 2003 | 842.59 Thousand CAD | -44.31% |
| 2002 | 1.51 Million CAD | -31.88% |
| 2001 | 2.22 Million CAD | 367.82% |
| 2000 | 474.8 Thousand CAD | 1452.61% |
| 1999 | 30.58 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 9.98 Million CAD | -15.48% |
| 2024 Q3 | 7.15 Million CAD | -26.67% |
| 2024 Q2 | 9.75 Million CAD | -2.28% |
| 2023 Q4 | 11.81 Million CAD | 14.97% |
| 2023 Q2 | 9.8 Million CAD | 17.42% |
| 2023 Q3 | 10.27 Million CAD | 4.75% |
| 2023 Q1 | 8.35 Million CAD | -1.17% |
| 2023 FY | 40.68 Million CAD | 64.36% |
| 2022 FY | 24.75 Million CAD | 256.86% |
| 2022 Q3 | 5.91 Million CAD | 19.8% |
| 2022 Q1 | 5.45 Million CAD | 122.02% |
| 2022 Q2 | 4.93 Million CAD | -9.58% |
| 2022 Q4 | 8.45 Million CAD | 42.99% |
| 2021 FY | 6.93 Million CAD | 31.88% |
| 2021 Q1 | 1.16 Million CAD | 19.58% |
| 2021 Q3 | 1.63 Million CAD | -2.36% |
| 2021 Q4 | 2.45 Million CAD | 50.16% |
| 2021 Q2 | 1.67 Million CAD | 43.82% |
| 2020 Q2 | 1.72 Million CAD | 25.84% |
| 2020 Q1 | 1.37 Million CAD | -23.59% |
| 2020 Q4 | 974.75 Thousand CAD | -17.84% |
| 2020 Q3 | 1.18 Million CAD | -31.28% |
| 2020 FY | 5.25 Million CAD | 31.23% |
| 2019 Q3 | 877.3 Thousand CAD | 42.81% |
| 2019 Q1 | 720.87 Thousand CAD | -13.74% |
| 2019 FY | 4 Million CAD | 8.14% |
| 2019 Q4 | 1.79 Million CAD | 104.68% |
| 2019 Q2 | 614.31 Thousand CAD | -14.78% |
| 2018 Q1 | 769.19 Thousand CAD | -22.56% |
| 2018 FY | 3.7 Million CAD | 40.21% |
| 2018 Q4 | 835.66 Thousand CAD | -24.86% |
| 2018 Q3 | 1.11 Million CAD | 12.42% |
| 2018 Q2 | 989.36 Thousand CAD | 28.62% |
| 2017 Q2 | 675 Thousand CAD | 111.11% |
| 2017 Q1 | 319.74 Thousand CAD | 66.56% |
| 2017 FY | 2.64 Million CAD | 5.67% |
| 2017 Q4 | 993.27 Thousand CAD | 51.55% |
| 2017 Q3 | 655.39 Thousand CAD | -2.9% |
| 2016 Q3 | 987.29 Thousand CAD | 51.12% |
| 2016 Q4 | 191.96 Thousand CAD | -80.56% |
| 2016 FY | 2.5 Million CAD | -13.31% |
| 2016 Q1 | 668.98 Thousand CAD | -24.99% |
| 2016 Q2 | 653.32 Thousand CAD | -2.34% |
| 2015 Q4 | 891.91 Thousand CAD | 32.68% |
| 2015 Q2 | 682.88 Thousand CAD | 6.93% |
| 2015 Q3 | 672.24 Thousand CAD | -1.56% |
| 2015 Q1 | 638.64 Thousand CAD | -7.07% |
| 2015 FY | 2.88 Million CAD | 3.3% |
| 2014 Q3 | 756.14 Thousand CAD | -0.67% |
| 2014 FY | 2.79 Million CAD | 35.27% |
| 2014 Q4 | 687.19 Thousand CAD | -9.12% |
| 2014 Q2 | 761.26 Thousand CAD | 25.02% |
| 2014 Q1 | 608.92 Thousand CAD | 9.75% |
| 2013 Q4 | 554.82 Thousand CAD | 39.66% |
| 2013 Q2 | 569.51 Thousand CAD | 4.78% |
| 2013 Q1 | 543.54 Thousand CAD | -41.7% |
| 2013 FY | 2.06 Million CAD | -22.34% |
| 2013 Q3 | 397.25 Thousand CAD | -30.25% |
| 2012 FY | 2.65 Million CAD | 30.76% |
| 2012 Q1 | 627.71 Thousand CAD | 25.92% |
| 2012 Q4 | 932.36 Thousand CAD | 70.25% |
| 2012 Q2 | 686.49 Thousand CAD | 9.36% |
| 2012 Q3 | 547.66 Thousand CAD | -20.22% |
| 2011 Q1 | 525.32 Thousand CAD | 6.84% |
| 2011 FY | 2.03 Million CAD | 10.25% |
| 2011 Q4 | 498.51 Thousand CAD | 13.04% |
| 2011 Q3 | 441 Thousand CAD | -22.48% |
| 2011 Q2 | 568.86 Thousand CAD | 8.29% |
| 2010 FY | 1.84 Million CAD | 24.09% |
| 2010 Q2 | 425.68 Thousand CAD | -5.11% |
| 2010 Q3 | 478.71 Thousand CAD | 12.46% |
| 2010 Q4 | 491.67 Thousand CAD | 2.71% |
| 2010 Q1 | 448.61 Thousand CAD | -1.21% |
| 2009 Q2 | 389.45 Thousand CAD | 35.59% |
| 2009 FY | 1.48 Million CAD | -47.54% |
| 2009 Q3 | 355.56 Thousand CAD | -8.7% |
| 2009 Q4 | 454.1 Thousand CAD | 27.71% |
| 2009 Q1 | 287.22 Thousand CAD | -53.77% |
| 2008 Q1 | 644.19 Thousand CAD | -37.45% |
| 2008 Q4 | 621.27 Thousand CAD | 25.31% |
| 2008 FY | 2.83 Million CAD | -23.77% |
| 2008 Q3 | 495.77 Thousand CAD | -54.98% |
| 2008 Q2 | 1.1 Million CAD | 70.96% |
| 2007 Q4 | 1.02 Million CAD | -6.01% |
| 2007 Q3 | 1.09 Million CAD | -4.69% |
| 2007 Q1 | 454.31 Thousand CAD | 1266.29% |
| 2007 Q2 | 1.14 Million CAD | 153.09% |
| 2007 FY | 3.71 Million CAD | 178.25% |
| 2006 Q4 | -38.95 Thousand CAD | -127.27% |
| 2006 FY | 1.33 Million CAD | 210.01% |
| 2006 Q2 | 1.13 Million CAD | 1028.35% |
| 2006 Q3 | 142.87 Thousand CAD | -87.38% |
| 2006 Q1 | 100.3 Thousand CAD | 6.71% |
| 2005 Q1 | 81.82 Thousand CAD | -35.36% |
| 2005 Q2 | 159.13 Thousand CAD | 94.48% |
| 2005 Q3 | 95.99 Thousand CAD | -39.68% |
| 2005 Q4 | 93.99 Thousand CAD | -2.08% |
| 2005 FY | 430.94 Thousand CAD | -34.46% |
| 2004 FY | 657.48 Thousand CAD | -21.97% |
| 2004 Q4 | 126.58 Thousand CAD | -29.99% |
| 2004 Q3 | 180.8 Thousand CAD | 9.0% |
| 2004 Q2 | 165.87 Thousand CAD | -9.96% |
| 2004 Q1 | 184.23 Thousand CAD | 53.98% |
| 2003 Q1 | 281.74 Thousand CAD | 15.29% |
| 2003 Q3 | 191.19 Thousand CAD | -23.53% |
| 2003 FY | 842.59 Thousand CAD | -44.31% |
| 2003 Q4 | 119.64 Thousand CAD | -37.42% |
| 2003 Q2 | 250.01 Thousand CAD | -11.26% |
| 2002 FY | 1.51 Million CAD | -31.88% |
| 2002 Q3 | 327.94 Thousand CAD | -30.26% |
| 2002 Q2 | 470.25 Thousand CAD | -0.05% |
| 2002 Q1 | 470.47 Thousand CAD | 0.0% |
| 2002 Q4 | 244.36 Thousand CAD | -25.49% |
| 2001 FY | 2.22 Million CAD | 367.82% |
| 2000 FY | 474.8 Thousand CAD | 1452.61% |
| 1999 FY | 30.58 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.83 Million CAD | -365.439% |
| Eupraxia Pharmaceuticals Inc. | 37.92 Million CAD | -8.456% |
| Helix BioPharma Corp. | 9.35 Million CAD | -339.571% |
| Microbix Biosystems Inc. | 10.21 Million CAD | -302.54% |
| Medicenna Therapeutics Corp. | 19.66 Million CAD | -109.178% |
| Satellos Bioscience Inc. | 6.64 Million CAD | -518.878% |
| Oncolytics Biotech Inc. | 33.79 Million CAD | -21.721% |